Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BENJAMIN LEE KITCHENS

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1841637477
CMS profile
1860929
Location
DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$84,261.37

129 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BENJAMIN LEE KITCHENS

NPI 1841637477 · CMS profile ID 1860929

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

DALLAS, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1841637477?year=2025&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BENJAMIN LEE KITCHENS, NPI 1841637477, CMS profile ID 1860929. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1841637477?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). BENJAMIN LEE KITCHENS, NPI 1841637477, CMS profile ID 1860929. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1841637477?year=2025&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
BENJAMIN LEE KITCHENS, NPI 1841637477, CMS profile ID 1860929, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 129 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1841637477?year=2025&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

129 matching records · $84,261.37 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 129 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 129.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Astellas Pharma US Inc $237.6008/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238676923 CMS
Astellas Pharma US Inc $290.8808/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238677107 CMS
Astellas Pharma US Inc $551.5408/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238677227 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,020.0008/14/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1223793959 CMS
AstraZeneca Pharmaceuticals LP $106.2108/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207286638 CMS
AstraZeneca Pharmaceuticals LP $1,005.0008/08/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1206170269 CMS
Incyte Corporation $1,720.0008/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226018313 CMS
Incyte Corporation $125.8508/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226169449 CMS
Merck Sharp & Dohme LLC $15.0408/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238151922 CMS
Incyte Corporation $124.6807/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226041860 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,530.0007/31/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1223794047 CMS
JAZZ PHARMACEUTICALS INC. $34.9707/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234317820 CMS
Astellas Pharma US Inc $396.8707/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238589470 CMS
Astellas Pharma US Inc $93.4107/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238654186 CMS
Astellas Pharma US Inc $735.0007/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238654236 CMS
Astellas Pharma US Inc $3,850.0007/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238654248 CMS
Astellas Pharma US Inc $275.0007/25/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238589468 CMS
Incyte Corporation $23.7607/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226167762 CMS
Incyte Corporation $3,655.0007/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226169875 CMS
Karyopharm Therapeutics Inc. $26.3807/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246642945 CMS
ABBVIE INC. $7.7707/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202209689 CMS
ADC THERAPEUTICS AMERICA, INC. $21.1207/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246121595 CMS
Takeda Pharmaceuticals U.S.A., Inc. $113.0906/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1223940896 CMS
Incyte Corporation $30.0006/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226139904 CMS
Incyte Corporation $30.0006/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226139908 CMS
Incyte Corporation $96.4306/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226169375 CMS
Incyte Corporation $60.0006/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226169459 CMS
Incyte Corporation $204.0606/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226170131 CMS
Incyte Corporation $534.9606/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226170151 CMS
Incyte Corporation $206.0006/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1226169107 CMS
Merck Sharp & Dohme LLC $33.8206/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238151924 CMS
Incyte Corporation $16.3506/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226129927 CMS
ABBVIE INC. $6.1706/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202209687 CMS
AstraZeneca Pharmaceuticals LP $10.8805/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206737700 CMS
Incyte Corporation $215.0005/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226042850 CMS
ABBVIE INC. $16.6705/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202209685 CMS
Syndax Pharmaceuticals, Inc. $24.3505/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238992198 CMS
AstraZeneca Pharmaceuticals LP $121.8605/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1207041080 CMS
ABBVIE INC. $18.4605/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1202209683 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,550.0005/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1223794189 CMS
Karyopharm Therapeutics Inc. $21.7605/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246642941 CMS
Gilead Sciences, Inc. $15.9705/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234565708 CMS
PFIZER INC. $26.0405/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1229107455 CMS
Janssen Biotech, Inc. $24.6405/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174991153 CMS
Incyte Corporation $21.5104/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226078591 CMS
Astellas Pharma US Inc $122.1904/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1238631981 CMS
Astellas Pharma US Inc $60.0604/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238632241 CMS
Astellas Pharma US Inc $836.8704/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238632279 CMS
Astellas Pharma US Inc $148.9504/21/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1238632507 CMS
Astellas Pharma US Inc $3,300.0004/21/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1238632695 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $880.63 36
PY2020 $1,099.52 22
PY2021 $853.05 31
PY2022 $800.27 28
PY2023 $25,208.25 85
PY2024 $63,929.86 121
PY2025 $84,261.37 129

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $123,375.00 46
PY2024 Principal investigator $83,071.00 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

46 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 12/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744656
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 12/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742285
Principal investigator 1 Genentech, Inc. $2,800.00 12/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211681170
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 11/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744654
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 11/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742283
Principal investigator 1 Genentech, Inc. $2,800.00 11/05/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211681078
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 11/05/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742281
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744652
Principal investigator 1 Genentech, Inc. $2,800.00 10/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680911
Principal investigator 1 Genentech, Inc. $2,800.00 10/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680931
Principal investigator 1 Genentech, Inc. $2,800.00 10/10/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211681016
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 10/08/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742279
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 09/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744632
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 09/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742277
Principal investigator 1 Genentech, Inc. $2,800.00 09/12/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680741
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 08/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744634
Principal investigator 1 Genentech, Inc. $2,800.00 08/01/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680287
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 08/01/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742275
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 07/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744636
Principal investigator 1 Genentech, Inc. $2,500.00 07/21/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675868
Principal investigator 1 Genentech, Inc. $2,800.00 07/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680425
Principal investigator 1 Genentech, Inc. $2,800.00 07/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680561
Principal investigator 1 Genentech, Inc. $2,800.00 07/02/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680591
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 06/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744638
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742273
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 05/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744640
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742269
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 05/28/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742271
Principal investigator 1 Genentech, Inc. $2,800.00 05/07/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211680239
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $975.00 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744642
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 04/30/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744644
Principal investigator 1 Genentech, Inc. $2,500.00 04/23/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675825
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742261
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 04/11/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742263
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 03/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744646
Principal investigator 1 Genentech, Inc. $4,500.00 03/26/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675792
Principal investigator 1 Genentech, Inc. $2,800.00 03/12/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211679911
Principal investigator 1 ABBVIE INC. $19,000.00 03/07/2025 Non-covered Recipient Entity
TEXAS ONCOLOGY - DALLAS - WORTH STREET
M24-052 - A Study to Assess the Dose Adverse Events and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2) No dispute reported 06/30/2026 1202459684
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 02/28/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744648
Principal investigator 1 Genentech, Inc. $2,800.00 02/26/2025 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC No dispute reported 06/30/2026 1211679945
Principal investigator 1 Genentech, Inc. $2,500.00 02/14/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675733
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 02/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742265
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 02/07/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742267
Principal investigator 1 Genentech, Inc. $2,500.00 02/04/2025 Non-covered Recipient Entity
UNITED STATES ONCOLOGY RESEARCH LLC
ATEZOLIZUMAB AND BEVACIZUMAB TIRAGOLUMAB IN 1L UNRESECTABLE HCC PTS No dispute reported 06/30/2026 1211675756
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 01/31/2025 Non-covered Recipient Entity
Texas Oncology
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233744650
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $3,000.00 01/17/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer. No dispute reported 06/30/2026 1233742259